Opendata, web and dolomites

LIMA SIGNED

Liquid biopsies and Imaging for improved cancer care

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "LIMA" data sheet

The following table provides information about the project.

Coordinator
PHILIPS ELECTRONICS NEDERLAND BV 

Organization address
address: HIGH TECH CAMPUS 52
city: EINDHOVEN
postcode: 5656 AG
website: www.philips.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://lima-project.eu/
 Total cost 6˙292˙873 €
 EC max contribution 6˙292˙873 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PHILIPS ELECTRONICS NEDERLAND BV NL (EINDHOVEN) coordinator 813˙093.00
2    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 1˙606˙347.00
3    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 1˙077˙563.00
4    ALS AUTOMATED LAB SOLUTIONS GMBH DE (JENA) participant 547˙145.00
5    AGENA BIOSCIENCE GMBH DE (HAMBURG) participant 517˙742.00
6    STILLA TECHNOLOGIES FR (VILLEJUIF) participant 483˙532.00
7    ANGLE EUROPE LIMITED UK (GUILDFORD) participant 469˙550.00
8    INSTITUT REGIONAL DU CANCER DE MONTPELLIER FR (MONTPELLIER) participant 398˙070.00
9    Philips GmbH DE (Hamburg) participant 265˙795.00
10    DIADX FR (LES MATELLES) participant 114˙033.00

Map

 Project objective

LIMA’s overall objective is to develop and validate technologies and tools to include liquid biopsies in the clinical workflow, aiming at introducing a more precise and dynamic genetic characterization of tumor at the diagnosis and during treatment phases. This will be done by combining molecular information from liquid biopsies and direct in-vivo tumor characterization from advanced MR imaging, taking into account the current clinical workflow. The LIMA project will be based on following 5 conceptual pillars: 1. A robust method to measure and genomically analyze ct-DNA for tumor-driving mutations, which can be measured in a quantitative manner allowing therapy response prediction and monitoring. 2. A workflow for Circulating Tumor Cell isolation and computational model-based quantitative signal pathway analysis on single CTC mRNA expression levels. This allows for assessment of tumor heterogeneity in pathway activity (to relate back to tumor heterogeneity), targeted therapy response prediction and monitoring 3. Correlation of computational, model-based cancer pathway activity assessment from cancer tissue samples before and after neoadjuvant treatment and from liquid biopsies with MR imaging features. 4. Advance in MR imaging to better probe and image the cancer lesion and its microenvironment 5. Clinical analysis, correlating liquid biopsy/imaging –based results to clinical outcome, that is the response to (targeted drug) neoadjuvant therapy in selected breast cancer and rectal cancer patients. These 5 pillars will be investigated in longitudinal observational studies that will follow patients undergoing neoadjuvant treatment (either chemotherapy or targeted therapy or the combination) for primary rectal and breast cancer. LIMA will demonstrate that prediction of drug therapy response, monitoring of response and detection of resistance can be improved over the current state of the art.

 Publications

year authors and title journal last update
List of publications.
2019 A Otandault, P Anker, Z Al Amir Dache, V Guillaumon, R Meddeb, B Pastor, E Pisareva, C Sanchez, R Tanos, G Tousch, H Schwarzenbach, A R Thierry
Recent advances in circulating nucleic acids in oncology
published pages: 374-384, ISSN: 0923-7534, DOI: 10.1093/annonc/mdz031
Annals of Oncology 30/3 2020-04-07
2019 Romain Meddeb, Ekaterina Pisareva, Alain R. Thierry
Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA
published pages: 623-633, ISSN: 0009-9147, DOI: 10.1373/clinchem.2018.298323
Clinical Chemistry 65/5 2020-04-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ARREST-TB (2019)

Accurate, Rapid, Robust and Economical diagnostic technoliogieS for Tuberculosis

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

BRAINTIME (2020)

Molecular atlas of the brain across the human lifespan

Read More